Printer-friendly version

There is a common misconception that American prices for prescription medications are excessive because they are often higher than prices in Canada. This leads some people to suggest that the overall cost burden of prescription drug spending in the United States is unfair.

Printer-friendly version

Given Canadians' well-known concern for the environment, it may be difficult to find anyone in Canada who is against improving the quality of the environment. However, a reliance on unnecessarily costly and intrusive policies over the past several decades has likely turned some people against environmentalism. But there are a growing number of market-based policy options that would improve environmental quality at a lower cost and with less government intervention than in the past. These policies are a breath of fresh air because they are cost-effective, market-oriented, less intrusive, and more appealing to broader sections of the Canadian public.

Printer-friendly version

The Ontario government, under Premier Dalton McGuinty, is preparing to adopt a new energy plan that prescribes both the amount of electricity-generating capacity and the specific types.

Printer-friendly version

The Ontario government, under Premier Dalton McGuinty, is preparing to adopt a new energy plan.

Printer-friendly version

This report is the fourth installment in our ongoing research to assess the performance of labour markets and explain why results differ among jurisdictions. Indicators of labour performance such as job creation, unemployment, and productivity are used to assess Canadian provincial and US state labour market performance.

Printer-friendly version

This study measures the quality and quantity of Canada's stock of advanced medical technologies relative to what is available and being delivered in other developed nations. The study begins with a discussion of the benefits and cost savings that can result from investments in medical technologies.

Printer-friendly version

This is the Fraser Institute's third report comparing Canada-US price differences for the prescription drugs that are most important to Canadian seniors (aged 60 and older). This year's report analyzes prices for the drugs most commonly prescribed to Canadian seniors in 2007, and compares Canadian and American prices for brand name and generic prescription drugs separately.